KURA Kura Oncology, Inc.

NASDAQ
$7.57

Kura Oncology, Inc. (KURA) is confirmed to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.83 per share.

Kura Oncology Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.83)
Rev est $22.2M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kura Oncology, Inc.

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.